Last reviewed · How we verify
ABX-EGF
ABX-EGF is a recombinant human heparin-binding EGF-like growth factor.
ABX-EGF is a recombinant human heparin-binding EGF-like growth factor. Used for Diabetic foot ulcers.
At a glance
| Generic name | ABX-EGF |
|---|---|
| Sponsor | Amgen |
| Drug class | growth factor |
| Target | EGF receptor |
| Modality | Small molecule |
| Therapeutic area | Wound healing |
| Phase | Phase 2 |
Mechanism of action
It is used to stimulate wound healing and tissue repair. ABX-EGF works by binding to the EGF receptor, which is involved in cell growth and differentiation.
Approved indications
- Diabetic foot ulcers
Common side effects
- Injection site reaction
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) (PHASE2)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery (PHASE1, PHASE2)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery (PHASE1, PHASE2)
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABX-EGF CI brief — competitive landscape report
- ABX-EGF updates RSS · CI watch RSS
- Amgen portfolio CI